Editas Medicine, Inc. (EDIT)
1.76
-0.01
(-0.56%)
USD |
NASDAQ |
Nov 19, 10:35
Editas Medicine Total Return Level : 1.77 for Nov. 18, 2026
Total Return Level Chart
Historical Total Return Level Data
| Date | Value |
|---|---|
| November 18, 2026 | 1.77 |
| November 17, 2026 | 1.825 |
| November 16, 2026 | 1.87 |
| November 13, 2026 | 2.17 |
| November 12, 2026 | 2.14 |
| November 11, 2026 | 2.38 |
| November 10, 2026 | 2.505 |
| November 09, 2026 | 2.75 |
| November 06, 2026 | 2.57 |
| November 05, 2026 | 2.55 |
| November 04, 2026 | 2.72 |
| November 03, 2026 | 2.60 |
| November 02, 2026 | 2.57 |
| October 30, 2026 | 2.67 |
| October 29, 2026 | 2.93 |
| October 28, 2026 | 2.95 |
| October 27, 2026 | 2.60 |
| October 26, 2026 | 2.40 |
| October 23, 2026 | 2.40 |
| October 22, 2026 | 2.49 |
| October 21, 2026 | 2.51 |
| October 20, 2026 | 2.58 |
| October 19, 2026 | 2.42 |
| October 16, 2026 | 2.35 |
| October 15, 2026 | 2.44 |
| Date | Value |
|---|---|
| October 14, 2026 | 2.27 |
| October 13, 2026 | 2.445 |
| October 12, 2026 | 2.75 |
| October 09, 2026 | 2.90 |
| October 08, 2026 | 2.84 |
| October 07, 2026 | 2.75 |
| October 06, 2026 | 2.73 |
| October 05, 2026 | 2.79 |
| October 02, 2026 | 2.62 |
| October 01, 2026 | 2.52 |
| September 30, 2026 | 2.57 |
| September 29, 2026 | 2.59 |
| September 28, 2026 | 2.51 |
| September 25, 2026 | 2.58 |
| September 24, 2026 | 2.75 |
| September 23, 2026 | 2.69 |
| September 22, 2026 | 2.92 |
| September 21, 2026 | 2.83 |
| September 18, 2026 | 2.70 |
| September 17, 2026 | 2.72 |
| September 16, 2026 | 2.71 |
| September 15, 2026 | 2.63 |
| September 14, 2026 | 2.74 |
| September 11, 2026 | 2.70 |
| September 10, 2026 | 2.65 |
Total Return Level Definition
The total return level allows investors to view the performance of a security inclusive of both price appreciation and dividends/distributions. Total return level is seen as the most accurate calculation that produces returns consistent with most other sources.
Total Return Level Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Return Level Benchmarks
| Alnylam Pharmaceuticals, Inc. | 149.40 |
| Vertex Pharmaceuticals, Inc. | 536.45 |
| Recursion Pharmaceuticals, Inc. | 2.825 |
| Halozyme Therapeutics, Inc. | 95.80 |
| Novavax, Inc. | 7.96 |